NeuroOne® Spinal Cord Stimulation Electrode Technology to be Featured at The Business of Pain Conference
Minimally invasive technology would allow for percutaneous placement of a paddle electrode
Renowned pain specialist Dr. Sean Li to present on this innovative tool for lower back pain
EDEN PRAIRIE, Minn., Sept. 24, 2024 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that its percutaneous paddle technology will be featured at The Business of Pain Meeting September 26th – 29th at the Loew’s Vanderbilt Hotel in Nashville, TN.
Dr. Sean Li, course director and expert in pain management, will be presenting during the meeting. He has made extensive contributions to the field of interventional pain management through his research, clinical practice and leadership. He is currently the President of the New Jersey Society of Interventional Pain Physicians and the Treasurer of the American Society of Pain and Neuroscience.
Dr Li commented, “I believe this thin film electrode technology unlocks the full potential of a surgically placed paddle electrode while preserving the benefits of a percutaneous placed electrode. This is the most advanced percutaneous spinal cord stimulation electrode I have worked with and believe it offers the best of both worlds. From my own experience, I believe it has the potential to improve the current treatment for patients suffering with chronic lower back pain.”
NeuroOne estimates the current spinal cord stimulation market to be approximately $3 billion worldwide given the large addressable patient populations with unmet clinical needs.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the potential for NeuroOne’s technology to improve the current treatment for patients suffering with chronic lower back pain, and the size of the current spinal cord stimulation market.. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages, risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to our ability to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
“Caution: Federal law restricts this device to sale by or on the order of a physician”
Contact:
800-631-4030
ir@nmtc1.com
